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Objectives: To investigate the hypothesis that persistence of apical contraction into 
diastole is linked to reduced myocardial perfusion and chest pain. 
Background: Apical hypertrophic cardiomyopathy (HCM) is defined by left 
ventricular (LV) hypertrophy predominantly of the apex. Hyperdynamic contractility 
resulting in obliteration of the apical cavity is often present. Apical HCM can lead to 
drug-refractory chest pain. 
Methods: We retrospectively studied 126 subjects; 76 with apical HCM and 50 
controls (31 with asymmetrical septal hypertrophy (ASH) and 19 with non-cardiac 
chest pain and culprit free angiograms and structurally normal hearts). Perfusion 
cardiac magnetic resonance imaging (CMR) scans were assessed for myocardial 
perfusion reserve index (MPRi), late gadolinium enhancement (LGE), LV volumes 
(muscle and cavity) and regional contractile persistence (apex, mid and basal LV).   
Results: In apical HCM, apical MPRi was lower than in normal and ASH controls 
(p<0.05). In apical HCM, duration of contractile persistence was associated with 
lower MPRi (p<0.01) and chest pain (p<0.05). In multivariate regression, contractile 
persistence was independently associated with chest pain (p<0.01) and reduced 
MPRi (p<0.001).
Conclusion:  In apical HCM, regional contractile persistence is associated with 
impaired myocardial perfusion and chest pain. As apical myocardium makes limited 
contributions to stroke volume, apical contractility is also largely ineffective. 
Interventions to reduce apical contraction and/or muscle mass are potential 






























































ASH = asymmetrical septal hypertrophy
CMR = cardiac magnetic resonance
EF = ejection fraction
FWHM = full width half max 
HCM = hypertrophic cardiomyopathy 
LGE = late gadolinium enhancement 
LV = left ventricular
LVH = left ventricular hypertrophy
MPRi = myocardial perfusion reserve index
MWT = maximal wall thickness
PMT = papillary muscles and trabeculae 
RV = right ventricular
SAX = short axis 
SSFP = steady state free precession cine
SV = stroke volume
%CC = percentage of the cardiac cycle






























































Hypertrophic cardiomyopathy (HCM) is characterised by marked left ventricular (LV) 
hypertrophy (LVH) [1].  Patients frequently experience troubling chest pain [2-5].  
Several studies demonstrate myocardial perfusion abnormalities in HCM [6-10] and 
others describe biochemical evidence for myocardial ischaemia [11, 12].  In the 
absence of coronary disease or LV outflow obstruction, microvascular disease is 
often assumed to be the cause of myocardial ischaemia.  This assumption is based 
on a few studies that report structural abnormalities of the microvasculature [13-16].  
Notably, limited data associates structural changes with perfusion abnormalities or 
chest pain [15, 17]. 
Myocardial perfusion occurs almost exclusively in diastole and perfusion pressure is 
greatest in early diastole when suction force due to decompression of the myocardial 
microcirculation also augments flow [18].  We hypothesised that regional 
prolongation of systolic contractility into early diastole is associated with reduced 
myocardial perfusion in HCM.
The aim of this study was to examine associations between chest pain and 
myocardial perfusion with prolongation of contractility in patients with apical HCM 































































This is a retrospective, cross-sectional, observational cohort study based at the 
London Chest Hospital, UK. Consecutive cases (age ≥16 years) of apical HCM 
(August 2008-February 2013) were identified from the registry of a regional CMR 
centre where adenosine stress perfusion imaging was routinely performed in HCM. 
We also studied control cohorts. 
2.2.1Apical HCM Cohort
Morphologic criteria for apical HCM included a maximal end-diastolic LV wall 
thickness (MWT) ≥15 mm in the apical segments of the heart [1]. We excluded cases 
where basal septal exceeded apical wall thickness and individuals with left bundle 
branch block, atrial fibrillation or obstructive coronary disease (>50% narrowing in a 































































We identified two control groups:
a). Consecutive patients with the asymmetric septal hypertrophy (ASH) variant of 
HCM who had also undergone perfusion CMR imaging (control-HCM).
b). Normal controls identified through a low-intermediate risk chest pain pathway in 
whom coronary angiography and perfusion CMR were performed as part of a 
prospective research study comparing the diagnostic accuracies of these modalities 
(EVINCI: NCT00979199) [20].  All normal controls had angiographically normal 
coronary arteries and structurally normal hearts. 
2.3 Collection of Clinical Data
Demographic and symptomatic data were collected from electronic records. Chest 
pain was recorded as present or absent from preceding outpatient clinic letters or 
scan indication information. Missing data are reported.
2.4 Consent and Ethical Approval
This study complies with the declaration of Helsinki and was conducted as audit 
(Clinical Management of the Inherited and Acquired Heart Muscle Diseases, 
BartsHealth NHS Trust audit No. 5298). As per protocol, ethics committee approval 





























































2.5 CMR Image Acquisitions and Analysis
All studies were performed on a 1.5 T magnet (Achieva®, Philips Medical Systems) 
and images acquired using standard protocols, medication was not withheld prior to 
imaging. Briefly, balanced steady-state free precession cine (SSFP) images were 
acquired with 25-30 phases/cardiac cycle (8mm slice thickness, 2mm gap for short 
axis (SAX) images; typical voxel size 1.9 x 1.9 mm).  For perfusion imaging, 
gadolinium based contrast bolus (Dotarem®) was followed by saline flush. SAX 
images at basal, mid and apical LV level were obtained at peak stress (adenosine 
140 μg/Kg/min, 4 minutes) and at rest. For late gadolinium enhancement (LGE), T1 
weighted inversion-recovery gradient echo images were acquired approximately 10 
min after gadolinium (typical voxel 2.07 x 2.16 mm, slice thickness 8 mm, FOV 300 
mm).
2.5.1LV Dimensions and Mass
Endocardial and epicardial borders, including papillary muscles and trabeculae 
(PMT) within blood pool, were manually traced on SAX images in all cardiac phases 
(Extended MR Workspace®, Philips Medical Systems).  Ejection fraction (EF), stroke 
volume (SV) and LV mass were calculated. Regional (SAX) LV volume was 





























































2.5.2Measurement of Contractile Persistence
LV obliteration was measured by manually tracing endocardial and epicardial 
borders, including PMT within LV muscle volume, for each phase in the three SAX 
slices co-localising with those for basal, mid-LV and apical perfusion (Figure 1).  To 
standardise the cardiac cycle, data were resampled at 30 phases/cycle if cines were 
obtained at any different frequency (typically 25-30 phases). LV cavity obliteration 
was defined as endocardial area ≤ 0.2cm2 (approximately ½ voxel). Diastolic 
obliteration was that present in any cardiac phase after end-systole. End systole was 
defined as the phase where total LV volume was lowest (Figure 1A).  Contractile 
persistence duration was expressed as either percentage of the cardiac cycle (%CC) 
or diastole (%D) during which obliteration was present.
2.5.3Perfusion Analysis
The myocardial perfusion reserve index (MPRi) was calculated in basal, mid and 
apical SAX slices that were not separated into American Heart Association (AHA) 
segments (without segmentation) [21, 22].  Epicardial, endocardial and blood pool 
contours were manually traced.  After baseline correction, stress and rest signal 
intensity (SI) time curves were constructed.  Maximum upslope was measured using 
a 4-point window for the myocardium and a 2-point window for the blood pool and 
mean myocardial maximum upslope was obtained for basal, mid and apical SAX 































































Quantity of LGE on T1 weighted images was determined using the full-width half 
max (FWHM) technique (CMR42, Circle Cardiovascular Imaging Inc., Canada) [24, 
25].  The FWHM method was applied to the three SAX slices co-localizing with 
basal, mid and apex perfusion images and LGE was expressed, without 
segmentation, as %myocardium.
2.5.5 Intra- and Inter-observer Error
For intra-observer error, MPRi was measured in a random sample of 10 apical HCM 
twice (with a gap of 1 week), in a random order. For inter-observer error, two 
independent measurements of MPRi were made in 5 scans, in a random order, by 
two observers. All patient-identifiable information was removed from the scans and 
the observers blinded to all other results.
2.6 Statistical Analysis
Nominal and parametric baseline characteristics were compared with Chi-squared 
and paired or unpaired t-tests, respectively. Parametric and non-parametric 
intergroup differences were tested with one-way ANOVA and Kruskal-Wallis one-
way ANOVA tests respectively. Multivariate regression was performed in apical HCM 
patients to find variables predicting apical MPRi (linear regression) and chest pain 
(logistic regression). The pre-specified, independent (predictor) variables included 






























































Unless stated, data are presented as mean (SD), p-values are two-tailed and a value 
of less than 0.05 was considered statistically significant. Where appropriate, Fisher’s 
exact test corrected for small samples and post-hoc Bonferroni correction was used 
for differences between means. Analyses was performed using StatsDirect, (v2.7.9 






























































CMR images of sufficient quality were available from 126 subjects (76 apical HCM, 
31 ASH-controls and 19 normal controls). The baseline characteristics of the cohort 
are shown in Table 1. 
3.1 Global and Regional LV Morphological Characteristics
Apical-HCM and control-HCM patients had similar LV end-diastolic and end-systolic 
volumes (EDV and ESV), LV mass and MWT. EF was marginally greater in apical 
HCM.  
There were differences in regional morphology; apical and mid-LV end-diastolic 
cavity volumes were lower in apical than in control-HCM but similar at the base.  
The myocardial volume in the apical SAX slices was greater in apical HCM than 
control-HCM, but similar in the basal and mid-LV. These data are shown in Table 2.
Resting LV outflow tract obstruction was present in 12 (39%) control-HCM patients.  
In the 28 HCM-control patients where symptom status was available 11 (39%) had 
resting LVOTO. In this small selected group, differences in the proportions with chest 
pain were no different in those with resting LVOTO and those without (9 of 11 Vs. 11 





























































3.2 LV Cavity Obliteration
No normal controls demonstrated LV obliteration; the threshold for cavity obliteration 
was lower than end-systolic apical endocardial area in normal controls (3.3±1.4 cm2) 
by 2.2 standard deviations (98th percentile).  
In apical HCM, LV cavity obliteration was detected in the apex, mid and basal LV in 
79%, 32% and 3% respectively, and in 39%, 13% and 0% of control-HCM (χ2 
p<0.001 for apex, p=0.03 for mid). 
In apical HCM, LV cavity obliteration persisting into diastole was demonstrated in 
apical, mid and basal LV regions in 78%, 26% and 3% respectively, and in 26%, 
13% and 0% of control-HCM (χ2 p<0.001 for apex).
Cavity obliteration was present for median 32%CC in the apex (interquartile range 
13%-43%) and 0%CC in the mid (0-9%) in apical HCM; and for 8%CC (0-13%) and 
0%CC (0-0%), respectively, in control-HCM (p<0.001 for apex, p<0.05 for mid). 
When only diastolic cavity obliteration was assessed, this was for 33%D at the apex 
(12-44%) and 0%D in the mid (0-9%) in apical HCM and 12%D (0-13%) and 0%D (0-





























































3.3 Regional Myocardial Perfusion
MPRi at the apex in apical HCM (1.1±0.3) was lower than that in control-HCM 
(1.5±0.6; p<0.001) and normal controls (1.6±0.5; p<0.001). MPRi in the basal and 
mid LV were similar in apical and control-HCM groups (Table 2). In apical HCM, 
MPRi was lower in the apex than the base (1.1±0.3 and 1.3±0.4 respectively; 
p<0.001).  MPRi was also lower, in apical HCM, at the apex compared to the mid-LV 
(1.1±0.3 and 1.2±0.5 respectively; p=0.03).  MPRi at all three levels were similar in 
control-HCM and in normal controls.
3.4 Global and Regional Late Gadolinium Enhancement
Globally, %LGE in apical and control-HCM was similar. Regionally, in apical HCM, 
%LGE in the apex (7.3±8.0%) was greater than in the base (4.7±5.7%, p=0.007) and 
greater than in the apex of control-HCM (1.9±3.7%; p=0.002). There was a 
significant univariate association between %LGE and MWT in the apex of apical 
HCM (ρ=0.40, p<0.001).
3.5 Apical HCM
3.5.1Chest Pain and Myocardial Perfusion
To examine for associations between perfusion or chest pain with morphologic and 
functional abnormalities, we divided apical HCM into tertiles for LVH magnitude 






























































MWT tertiles had similar chest pain prevalence and regional apical MPRi (Table 3). 
%LGE was greatest in the highest MWT tertile; for all patients, there was a 
significant univariate correlation between MWT and %LGE (r=0.36, p=0.001), but not 
with MPRi (Table 4).
3.5.3Duration of Apical Cavity Obliteration
Apical obliteration persisted through a median of 50%D (interquartile range 44%-
55%) in the group with most obliteration (CIII), 33%D (29-37%) and 0%D (0-12%) in 
intermediate (CII) and least severe groups (CI) respectively. Most measures of 
global LV structure/function and %LGE were similar.
Chest pain was much more frequently reported in CIII (χ2 p<0.05; Table 3). Apical 
MPRi was lower in CIII patients than CI (p<0.001) and CII (p=0.007). For all apical 
HCM, both %D (r=-0.52, r2=0.27, p<0.001) and %CC (r=-0.54, r2=0.29, p<0.001) 
correlated with MPRi (Table 4, Figure 2A). 
3.6 Multivariate Analyses
Duration of contractile persistence, %CC, was independently associated with chest 
pain (p<0.005) and a reduction in apical MPRi (p<0.001) (Table 4).  Analyses for 





























































3.7 Inter- and Intra-observer Error
For the three areas of the left ventricle in 20 patients (n=60), the intra-observer mean 
difference in MPRi was -0.02 (95% CI; -0.10 to 0.041, p=0.52).  The inter-observer 































































This study shows for the first time that chest pain in apical HCM is associated with 
distinct contractile abnormalities. Our novel finding is that the persistence of apical 
contraction is strongly associated with chest pain and regional impairment in 
myocardial perfusion. We suggest that apical muscle exhibits pathological 
contractility into diastole, resulting in ischaemia and symptoms.
In comparison to other morphologic variants, apical HCM has a relatively benign 
prognosis in both Western and Asian populations [26, 27].  Reported prevalence of 
chest pain in patients with apical HCM cared for at tertiary centres varies widely 
between 30 and 92% and is frequently refractory to pharmacological therapy [26-32].  
Chest pain is commonly attributed to myocardial ischaemia, the cause of which is not 
well understood and several mechanisms including microvascular dysfunction, 
reduced capillary density and myocardial bridging have been implicated [33-35].
Early diastole is particularly important for myocardial perfusion [18].  We 
hypothesised that regional differences in persistence of early diastolic contractility 
could result in impaired myocardial perfusion in HCM.  In order to examine this 
hypothesis, we used CMR to assess regional contractility and MPRi in apical HCM 
and used two comparator cohorts to investigate morphologic and contractile 
abnormalities particular to apical HCM.  Notably, despite similar disease severity 
(including LV mass, max wall thickness and %LGE), LV cavity obliteration, a 
common feature of apical HCM, was considerably less frequently detected in ASH-
HCM, and was much less persistent when present.  Cavity obliteration was not 





























































The pathophysiology of chest pain in HCM is complex. In this study of apical HCM, 
almost all patients with contractile systolic persistence of >40% of cardiac cycle 
and/or MPRi<1 experienced chest pain (Figure 2B).  However, chest pain was also 
present in the absence of these two abnormalities in a substantial subgroup of 
patients, suggesting that other factors are contributing. Similarly, low MPRi is not 
always associated with contractile systolic persistence of >40%, suggesting that 
additional factors are at play [6, 36-38].
4.1 Implications for other HCM Variants
In apical HCM, cavity obliteration is easily detectable and quantifiable. Post-systolic 
regional contractile persistence in other variants/myocardial regions may be less 
readily discerned.  For example, in patients with ASH, an AHA-segmental rather than 
regional analysis of LV contraction would be required to demonstrate this 
phenomenon in the basal septum.  Analyses of differences in regional strain may 
help determine if this mechanism contributes to symptoms in other HCM variants, 






























































Our hypothesis is consistent with the efficacy of conventional drug therapies for 
symptomatic HCM that decrease contractility, prolong diastole and promote lusitropy. 
For drug-refractory chest pain, invasive options are only considered when there is 
dynamic LV obstruction [1];  such symptoms can be exceptionally difficult to manage 
in non-obstructive HCM. We present very preliminary evidence that therapies which 
manipulate contraction/relaxation on a global (with investigative molecules such as 
MYK-461/Mavacamten) or a regional basis (such as RV or LV pacing) may warrant 
further investigation in severely symptomatic apical HCM [31, 39, 40]. These 
investigations should be advanced in rigorous peer-reviewed prospective research 
settings.  Notably, the regional reduction of muscle mass (surgical and non-surgical 
myectomy) that has been advocated for some patients with severe forms of apical 
HCM may, in part, improve chest pain by interrupting this mechanism [30, 41]. 
4.3 Limitations
This single centre study retrospectively selects HCM patients that have undergone 
stress CMR. Stress CMR imaging is a routine component of our clinical evaluation of 
all HCM patients in the absence of contra-indications. In addition, several subjects 
scanned in our centre are managed in other centres, limiting available data and 
contributing to selection bias.  This also meant we were unable to index our CMR 
findings to body surface area.  There was a non-significant trend for apical HCM 
patients with more severe disease, in terms of apical contractile persistence, to be 
more likely to be treated with a beta-blocker and/or calcium channel antagonist.  
Differences in medical therapy may have affected LV contraction, but these are more 





























































A prospective study would include long-axis perfusion imaging to account for long-
axis systolic function, as well as more specialised quantitative perfusion techniques 
(for example by using a dual-bolus approach to assess myocardial blood flow 
(MBF)). Tissue tagging could provide additional data on regional differences in 
contraction and relaxation. Finally, hypercontractility would be assessed on images 
obtained during stress.  A prospective study could also include invasive perfusion 
pressure and volume measurements to further substantiate our observations.
5. Conclusions
In conclusion, duration of systolic cavity obliteration is associated with chest pain and 
impaired myocardial perfusion in apical HCM. We speculate that the prolongation of 
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Figure 1: Contractile persistence in three subjects.  Columns from left to right: long axis 
CMR images at end-diastole and end-systole respectively; typical endocardial area changes 
across the cardiac cycle, and; basal, mid and apical MPRi. Row (A) Apical HCM, (B) ASH-
HCM, (C) Normal control.
Figure 2: Panel A: Scatter plot demonstrating relation of MPRi and contractile persistence 
(%CC) in 76 apical HCM patients. As persistence increases, myocardial perfusion declines. 
The linear regression line and 95% CI are shown (MPRi=1.40 -0.0092*%CC; 95%CI of 
coefficient: -0.01 to -0.006; p<0.001). Panel B: Scatter plot demonstrating relation of MPRi 
and contractile persistence (%CC) in 66 apical HCM patients: 47 with (red markers) and 19 
without chest pain (blue markers) (chest pain data missing from 10 apical HCM patients). 
Almost all patients with contractile persistence >40% of cardiac cycle and/or MPRi <1 had 
chest pain (MPRi=1.39 -0.0088*%CC; 95%CI of coefficient: -0.01 to -0.005; p<0.001). 
Panels C and D: Box plots of contractile persistence (%CC) and MPRi according to chest 





































































Male, n (%) 47 (62) 23 (74) 14 (74)
Age at scan, average (SD) 58.6 (13) 62.0 (13) * 51.7 (11)
Ethnicity
Information available (n) 67 26 16
White, n (%) 16 (24) 9 (35) 6 (38)
Asian, n (%) 32 (48) 10 (39) 6 (38)
Black, n (%) 13 (19) 6 (23) 4 (25)
Mixed, n (%) 6 (9) 1 (4) 0 (0)
Treated Hypertension
Information available (n) 68 28 19
Present, n (%) 50 (74) † 22 (79) † 8 (42)
NYHA function class
Information available (n) 64 27
1, n (%) 36 (56) 10 (37)
2, n (%) 16 (25) 12 (44)
3, n (%) 12 (19) 5 (19)
Chest pain
Information available (n) 66 28
Present, n (%) 47 (71) 20 (71)




































































LV EDV (mL) 115 (29) 122 (33) 129 (34)
LV ESV (mL) 38 (17) * 47 (23) 51 (22)
EF (%) 68 (8) ** † 63 (10) 61 (8)
ED MWT (mm) 18.8 (3.4) *** 18.3 (2.5) *** 10.1 (2.0)
LV mass (g) 177 (64) *** 155 (42) *** 100 (33)
Endocardial area (cm2)
Base 15.1 (5.4) ** 15.5 (4.2) ** 19.9 (4.4)
Mid 9.3 (3.6) *** ††† 12.9 (4.6) *** 17.9 (3.2)
Apex 4.4 (2.4) *** ††† 8.7 (3.9) *** 12.8 (3.2)
Myocardial area (cm2)
Base 27.0 (6.7) *** 26.5 (7.4) *** 18.7 (5.5)
Mid 27.0 (6.8) *** 24.2 (7.2) *** 16.0 (4.7)
Apex 21.2 (7.8) ** †† 16.8 (6.4) ** 11.0 (3.3)
MPRi
Base 1.3 (0.4) ‡‡‡ 1.4 (0.6) 1.5 (0.5)
Mid 1.2 (0.5) ‡ 1.5 (0.6) 1.5 (0.4)
Apex 1.1 (0.3) *** ††† 1.5 (0.6) 1.6 (0.5)
All data presented as mean (SD).*:p<0.05, **:p<0.01, ***:p<0.001 vs. normal controls; 





























































Table 3: Differences between apical HCM patients divided into tertiles on the basis of LVH and apical contractile persistence (tertile 1 
best (n=26), 2 (n=25), tertile 3 worst (n=25), and for gender (male=47, female=29) 
 Apical MWT Contractile Persistence, % cardiac cycle Gender















Male, n (%) 14  (54) 14 (56) 19 (73) 18 (69) 16 (64) 13 (52)
Age (SD), years 62 (14) 59 (13) 56 (13) 58 (13) 59 (13) 59 (14) 56 (13) § 63 (13)
Chest pain, n (%) 16 (70) 14 (63) 17 (78) 13 (57) 15 (68) 19 (91) * 31 (76) 16 (64)
Apex MWT (SD), mm 17.9 (3.0) 18.9 (3.3) 19.8 (3.8) 19.5 (3.6) § 17.7 (2.8)
LV apical LGE (SD), % 5.4 (7.7) † 5.5 (6.9) † 11.0 (8.3) 7 (8) 6 (8) 9 (8) 9.0 (8.6) § 4.5 (6.0)
Apex contractile persistence
% CC (SD) 24 (18) 30 (20) 32 (20) 26 (20) 33 (18)
% D (SD) 21 (18) 26 (19) 29 (19) 4 (7) ††† ‡‡‡ 28 (6) ††† 45 (13) 23 (19) 29 (18)
Apical MPRi (SD) 1.1 (0.4) 1.2 (0.3) 1.0 (0.3) 1.3 (0.3) ††† 1.2 (0.3) †† 0.9 (0.3) 1.2 (0.3) 1.1 (0.4)
EF (SD), % 71 (8) 68 (6) 66 (9) 67 (9) 69 (8) 68 (8) 66 (9) § 71 (6)
LV mass (SD), g 151 (47) ††† 160 (43) †† 220 (76) 174 (67) 189 (69) 167 (56) 196 (67) §§ 146 (46)
LV ED volume (SD), ml 108 (27) 119 (31) 119 (29) 126 (33) 110 (30) 110 (21) 120 (32) 109 (22)
LV ES volume (SD), ml 33 (17) 39 (15) 42 (18) 43 (20) 35 (16) 35 (12) 42 (19) § 32 (11)
ED endocardial area (SD), cm2
Base 15 (5) 17 (6) 14 (6) 17 (6) 13 (5) 15 (5) 14 (6) 16 (5)
Mid 10 (3) † 10 (4) † 8 (3) 11 (3) †† ‡ 8 (4) 8 (3) 9 (4) 10 (4)
Apex 5 (2) 5 (3) 4 (2) 7 (2) † ‡ 4 (2) 3 (2) 5 (3) 4 (2)
ED myocardial area (SD), cm2
Base 26 (7) 26 (7) 30 (9) 28 (7) 29 (9) 25 (7) 29 (8) § 24 (7)
Mid 24 (6) ††† 26 (6) † 31 (7) 28 (7) 28 (7) 25 (7) 28 (7) §§ 25 (6)
Apex 18 (6) ††† 21 (5) †† 26 (7) 22 (6) 22 (7) 21 (7) 23 (6) 20 (7)
βBlocker and/or Ca antagonist (%) 95 70 85 96 77 72 77 86












































Table 4: Multivariate regression analyses for predictors of apical LGE, apical MPRi 
and chest pain
Multivariable ordinal logistic regression with apical LGE [none, mild (<10%), 
moderate (10-20%), severe(>20%)] as dependent variable in 76 patients
Independent variables OR p 95% Conf. Interval
Male 1.88 0.193 0.73 4.87
Age (years) 1.00 0.928 0.97 1.04
Apical MWT (mm) 1.21 0.008 1.05 1.39
Contractile persistence (%CC) 0.99 0.600 0.97 1.02
MPRi 0.43 0.298 0.09 2.09
Multivariable linear regression with apical MPRi as dependent variable in 76 
patients*
Independent variables Coef. p 95% Conf. Interval
Male 0.04 0.610 -0.11 0.18
Age (years) -0.002 0.467 -0.01 0.003
Apical LGE (%LV) -0.001 0.245 -0.01 0.004
Apical MWT (mm) -0.004 0.706 -0.03 0.02
Contractile persistence (%CC) -0.01 <0.001 -0.01 -0.01
Multivariable logistic regression with chest pain as dependent variable in 66 
patients **
Independent variables Odds Ratio p 95% Conf. Interval
Male 2.66 0.159 0.68 10.42
Age (years) 1.01 0.770 0.96 1.06
Apical LGE (%LV) 1.03 0.426 0.95 1.13
Apical MWT (mm) 1.02 0.858 0.82 1.27
Contractile persistence (%CC) 1.06 0.003 1.02 1.10
* Constant for linear regression model: 1.58, R2: 0.31
** 10 patients with missing chest pain data were not included
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